Translational Sciences is a PBC-based company founded by Dr. Guy Reed, dean of the University of Arizona College of Medicine – Phoenix. Recently Dean Reed appeared on Arizona Horizons on Arizona PBS to discuss Translational Sciences’ new drug TS23, which shows promise in dissolving blood clots and aneurisms that could cause strokes.
“Thirty five million people a year have blood clots; the problem is that many still die or are disabled because the only therapy that we have for dissolving those blood clots creates unacceptable bleeding in the brain,” Reed said, speaking to host Ted Simons.
Learn more about Dean Reed and the work he has done at the College of Medicine – Phoenix in a profile we did about him last year.
Translational Sciences’s TS23 is a “monoclonal antibody that attacks a protein in the blood”, Reed said. The technology is based off a small portion of the population with a genetic deficiency that makes blood clots easier to dissolve. The company signed an exclusive licensing agreement with CSL, a leading global biotechnology company, for TS23, according to a press release from CSL.
Watch the full interview on Arizona PBS here.